|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-12-14
|
|
pubmed:abstractText |
No effective chemotherapy for advanced hepatocellular carcinoma (HCC) exists. Expression of the platelet-derived growth factor receptor (PDGFR) has been demonstrated in HCC, which may derive from hepatic stem cells that express c-kit. The aim of this trial was to evaluate imatinib, a tyrosine kinase inhibitor of PDGFR and c-kit, in patients with advanced HCC and impaired liver function.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
363-71
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16319507-Adult,
pubmed-meshheading:16319507-Aged,
pubmed-meshheading:16319507-Antineoplastic Agents,
pubmed-meshheading:16319507-Carcinoma, Hepatocellular,
pubmed-meshheading:16319507-Cohort Studies,
pubmed-meshheading:16319507-Disease-Free Survival,
pubmed-meshheading:16319507-Enzyme Inhibitors,
pubmed-meshheading:16319507-Fibrosis,
pubmed-meshheading:16319507-Humans,
pubmed-meshheading:16319507-Immunohistochemistry,
pubmed-meshheading:16319507-Liver,
pubmed-meshheading:16319507-Liver Neoplasms,
pubmed-meshheading:16319507-Middle Aged,
pubmed-meshheading:16319507-Piperazines,
pubmed-meshheading:16319507-Protein Kinase Inhibitors,
pubmed-meshheading:16319507-Protein-Tyrosine Kinases,
pubmed-meshheading:16319507-Proto-Oncogene Proteins c-kit,
pubmed-meshheading:16319507-Pyrimidines,
pubmed-meshheading:16319507-Receptors, Platelet-Derived Growth Factor,
pubmed-meshheading:16319507-Stem Cells,
pubmed-meshheading:16319507-Time Factors,
pubmed-meshheading:16319507-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.
|
|
pubmed:affiliation |
Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Germany. florian.eckel@lrz.tum.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
